Solid organ transplantation (SOT) is a life-saving procedure and an established treatment for
patients with end-stage organ failure. However, transplantation is also accompanied by …

Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as
antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV …

Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …

This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …

The KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney
Disease (CKD) follows only 2 years after the original KDIGO 2020 Clinical Practice …

Background Diabetes is the commonest cause of chronic kidney disease (CKD). Both
conditions commonly co‐exist. Glucometabolic changes and concurrent dialysis in diabetes …

Background: The objective of this systematic review was to evaluate the efficacy and safety
profiles of sodium-glucose co-transporter 2 (SGLT-2) inhibitors for treatment of diabetes …

Post-transplantation diabetes mellitus (PTDM) may severely impact both short-and long-term
outcomes of kidney transplant recipients in terms of graft and patient survival. However …

Abstract Introduction Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors have
demonstrated kidney, cardiovascular and mortality benefits in the general population; …

Aims Atherosclerotic vascular disease has an inflammatory pathogenesis. Heme from
intraplaque haemorrhage may drive a protective and pro-resolving macrophage M2-like …